RhumbLine Advisers
SYRS

RhumbLine Advisers’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

RhumbLine Advisers’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-659
Closed -$3.4K – 4362
2024
Q2 		$3.4K Hold
659
– – ﹤0.01% 4138
2024
Q1 		$3.52K Hold
659
– – ﹤0.01% 4029
2023
Q4 		$5.13K Hold
659
– – ﹤0.01% 3977
2023
Q3 		$2.6K Hold
659
– – ﹤0.01% 4085
2023
Q2 		$2.08K Buy
+659
New +$2.12K ﹤0.01% 4211
2022
Q2 		– Sell
-6,387
Closed -$76K – 3259
2022
Q1 		$76K Sell
6,387
-279
-4% -$4.99K ﹤0.01% 2937
2021
Q4 		$217K Sell
6,666
-11
-0.2% -$445 ﹤0.01% 2815
2021
Q3 		$298K Buy
6,677
+205
+3% +$10K ﹤0.01% 2769
2021
Q2 		$353K Buy
6,472
+1,802
+39% +$107K ﹤0.01% 2725
2021
Q1 		$349K Sell
4,670
-78
-2% -$8.1K ﹤0.01% 2643
2020
Q4 		$515K Buy
4,748
+259
+6% +$23.6K ﹤0.01% 2436
2020
Q3 		$397K Sell
4,489
-403
-8% -$45.8K ﹤0.01% 2394
2020
Q2 		$522K Buy
4,892
+947
+24% +$85K ﹤0.01% 2326
2020
Q1 		$234K Buy
3,945
+6
+0.2% +$407 ﹤0.01% 2518
2019
Q4 		$272K Buy
3,939
+46
+1% +$2.79K ﹤0.01% 2642
2019
Q3 		$404K Sell
3,893
-27
-0.7% -$2.55K ﹤0.01% 2424
2019
Q2 		$363K Buy
3,920
+780
+25% +$54.3K ﹤0.01% 2507
2019
Q1 		$287K Sell
3,140
-101
-3% -$7.03K ﹤0.01% 2571
2018
Q4 		$181K Buy
3,241
+1,100
+51% +$83.6K ﹤0.01% 2762
2018
Q3 		$255K Sell
2,141
-106
-5% -$12.3K ﹤0.01% 2602
2018
Q2 		$229K Buy
2,247
+1,049
+88% +$130K ﹤0.01% 2676
2018
Q1 		$155K Buy
1,198
+172
+17% +$18.8K ﹤0.01% 2658
2017
Q4 		$100K Sell
1,026
-247
-19% -$33.2K ﹤0.01% 2774
2017
Q3 		$187K Buy
1,273
+41
+3% +$7.71K ﹤0.01% 2766
2017
Q2 		$198K Buy
+1,232
New +$194K ﹤0.01% 2764

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

RhumbLine Advisers's SYRS Position: Q3 2024 in Review

RhumbLine Advisers sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2024, closing a stake of 659 shares — an estimated $3.4K sold.

RhumbLine Advisers first reported a position in SYRS in Q2 2017 and held it in 25 quarters. The position peaked at $522K in Q2 2020. 65 funds tracked by Wall St. Rank hold SYRS as of Q3 2024.

  • RhumbLine Advisers reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 659 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2024, an estimated $3.4K.
  • RhumbLine Advisers first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 25 quarters.
  • RhumbLine Advisers's Syros Pharmaceuticals, Inc. Common Stock position peaked at $522K in Q2 2020.
  • 65 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.